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ABSTRACT 
Background: Cyclosporin A (CsA) has been a cornerstone of solid organ transplantation 
since its introduction to the market in the early 1980’s, and is a major part of the success of 
immunosuppression in the clinical setting. CsA is like many other immunosuppressive drugs, 
and has a narrow therapeutic window and large inter-individual variability. Highly variable 
drug exposure is associated with a high risk of organ rejection, and side effects like 
nephrotoxicity, infection, hepatotoxicity, and cancer. Obtaining the optimal exposure of the 
drug will not only prevent acute rejection, but also prolong the survival of the grafts, the 
organs, and inevitably the patients. 
The overall purpose was to develop a pharmacokinetic population model for further use in 
later studies to improve therapeutic drug monitoring of CsA in renal transplant patients. 
Specific goals for the thesis include testing different compartment models with different 
absorption and elimination profiles, screen for possible covariates that may improve the 
compartment model, and finally validate the model. 
Methods: Data was gathered from three separate studies, previously performed by the 
Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo. 49 
patients provided a total of 1027 plasma concentration samples and various patient 
demographics. By using the nonlinear mixed-effect modeling program NONMEM a 
pharmacokinetic population model was developed.  
Results: A 2-compartment model with an absorption lagtime gave the best fit for the 
cyclosporin A data, with CL/F = 26.1 L/h, Q/F = 20.5 L/h, VC/F = 77.7 L, VP/F = 342 L, ka = 
1.88 1/h, and ALAG = 0.452 h. Screening for covariates showed that age (years), body mass 
index (BMI, kg/m2), creatinine clearance (ml/min.), gender, height (m), lean body mass 
(LBM, kg), steroid dose (mg), post-transplantation time (weeks), and weight (kg) were 
significant to varying degrees. The data-splitting as recommended by Food and Drug 
Administration (FDA) was employed as an internal validation of the model. The resulting 
objective function value (OFV) was very variable and clearly showed that the model has a 
serious lack of robustness. The difference between the maximum and minimum value were 
253.09, which is significantly more than the maximum allowed value of < 3.84. Inclusion of 
 12 
covariates that proved to be statistically significant may possibly have had their clinical 
significance overestimated. The criteria set up for inclusion of covariates in to the final 
model, will need revision to possibly remove some covariates and hopefully stabilize the 
model. 
Conclusion: This model provides a good basis upon which a dosage regimen for cyclosporin 
A may be designed, though some further refinement may be needed to improve upon the 
models somewhat lack of robustness 
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1 INTRODUCTION 
1.1 PHARMACOKINETICS 
1.1.1 Introduction 
Pharmacokinetics (PK) describes the relationship of drug concentrations attained in different 
regions of the body with time, during and after drug input. The drug level-time relationship is 
related to adjustable elements of dose, dosage form, frequency and route of administration. 
Simply put, PK is what the body does to the drug. It may be viewed separately from 
pharmacodynamics (PD), which covers the relationship between drug concentration and the 
magnitude of effects produced with time. In simple terms, PD is what the drug does to the 
body [1-3]. 
The drug concentrations needed for PK/PD evaluation are rarely measured at the site of 
action. Instead more accessible sites are used to assess exposure to drugs. The two most 
commonly sampled fluids are blood and urine [2, 3]. 
For every drug there exists an 
optimal range, where the drug 
gives its desired effects with 
acceptable side-effect intensity 
and therapy will be successful. 
Below this range the exposure to 
the drug is to low to give an 
adequate response, while too 
high an exposure will result in 
undesired adverse effects. This 
optimal range is called the 
therapeutic window. It is however important to point out that the limits for the therapeutic 
window is individual and will vary between patients [2, 3]. 
Figure 1. Therapeutic window 
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Often in PK/PD evaluation there will be a difference between expected values and the true 
outcome. These differences or variations can be attributed to inter-individual and residual 
variability. Inter-individual variability can be explained as when calculating parameter values 
based on past research and experience, the parameter values for a specific individual will 
differ from the expected values because of true biological variability between individuals. 
Inter-individual variability makes up a substantial part of the differences in drug response, 
usually reflected by the variety of drug strengths on the market. The residual variability is a 
grouping of several variations, including intra-individual variability, inter-occasion 
variability (day-to-day or week-to-week), and error in measurement, dosage and modeling. 
All this variability arises because the mathematical calculations that are used to estimate and 
predict the parameters are just an oversimplification of our reality. An increase in 
unexplained random variability produces uncertainty in predicting and controlling drug 
concentrations, and is of particular importance because it may decrease the efficacy and 
safety of the drug. It is important to keep in mind that the variability that applies to drug 
response will equally apply to adverse effects [2-6].  
There are several factors that can influence the individual dose-concentration relationship, 
and this is recognized as variability in pharmacokinetic parameters. These factors include [2-
5]: 
• demographics; gender, body weight, body surface area (BSA), age, race etc. 
• environmental factors; smoking, diet, exposure to pollutants etc. 
• genetic phenotype of polymorphic cytochrome P450 isoforms that can affect the 
metabolism and clearance of drugs. 
• interactions with other drugs, co-medication 
• physiological factors; pregnancy and similar 
• pathophysiological factors; renal impairment, hepatic impairment, CHD, other disease 
states 
• other factors; circadian rhythm, adherence, food effect, timing of meals, physical 
activity, posture, stress  
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Variability, as properties of each individual that causes them to differ from an average 
individual, is called “fixed effects”. The other type of variability is called “random effects”, 
in the sense that they can not be predicted in advance. Random effects are comprised of 
inter-individual and residual variability, and quantify the amount of variability unexplained 
by the fixed effects [4, 7]. 
Studies using traditional pharmacokinetics do not deal with inter-individual variability, but 
rather estimates PK-averages. The inter-individual variability is viewed as a factor that needs 
to be overcome through rigorous and restrictive study design, which in turn makes the study 
design more complex. The patients that are selected for trial are standardized and 
homogenized. This creates artificial conditions which do not accurately represent the 
intended use of the drug [4, 5]. 
1.1.2 Population pharmacokinetics 
The main goals of population pharmacokinetics (PPK) are to quantitatively assess the 
pharmacokinetic parameters, and the inter-individual and residual variability in drug 
absorption, distribution, metabolism and excretion (ADME). PPK highly contrasts with 
traditional pharmacokinetics. With PPK the goal is not to homogenize and standardize the 
patients, from which the data is gathered. PPK seeks to obtain all relevant information from 
the patients that are representative of those in whom the drug will be used clinically. This 
means that all sources of variability, including inter-individual, intra-individual, inter-
occasion and unexplained variability, must be identified, explained and quantified. The 
clinical significance can be evaluated by identifying the measurable factors that is associated 
with change in the relationship between dose, concentration, response and pathophysiology, 
and the extent of these changes. Dosage may then be modified appropriately to maximize 
drug safety and efficacy [4-6].  
With PPK it is possible to gain integrated information on PK from relatively sparse data, 
dense data or from a combination of both. Data can be divided into two groups: experimental 
data and observational (population) data. Experimental data are gathered through traditional 
studies, where there is controlled design and extensive blood sampling, i.e. dense data. 
Observational data on the other hand are gathered during routine clinical care or as a 
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supplement in a study designed and carried out for another purpose. These data are usually 
sparse, collected at various times, and unbalanced [5, 6].  
PPK also seeks to quantify the distribution and spread of the variability. The measure of 
spread is termed variance, 2σ . By accounting for the variance in the model system, PPK can 
define the dispersion of drug exposure more precisely, thus lessening dispersion. By gaining 
more accurate and precise estimation of the PPK parameters and their variance, it is less 
probable that a concentration-driven toxicity will be encountered. This is because as the 
variance decreases, there will be fewer outliers [8]. 
PPK is most valuable in situations where the population in which the drug is intended is 
heterogeneous and when there is a narrow therapeutic window [6].  
There are 3 interwoven steps in which population pharmacokinetics data analysis can be 
done [5, 6]; 
• Exploratory data analysis; where statistical and graphical techniques are used to uncover 
patterns and features in the population data. 
• Pharmacokinetic population model development; where criteria and rationale for choice 
of model is set, and the steps taken to build the model is outlined 
• Model validation; where the objective is to examine if the model describes the data in a 
good manner and produces a good fit. 
1.1.3 Compartmental theory 
Human anatomy and physiology is so complex that truly modelling how the body handles 
drugs is difficult. However it is often possible to simplify the body with regards to PK 
modelling into relatively few compartments [2, 3]. 
Compartments make up a basic model for drug absorption and disposition. There are two 
classes of compartments; transfer and chemical. Transfer compartments refer to different 
locations in the body. Chemical compartments are not locations, but refer to compartments 
that differ chemically. As in metabolism, the metabolite will be in a different chemical 
compartment than the drug itself. An often used representation of compartment models is the 
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2-compartment model as illustrated in 
figure 2. It shows drug administered and 
eliminated from the first compartment. 
Drug also distributes back and forth 
between the first and second 
compartment. It is important to point out 
that it is the plasma-concentration data 
that defines the model. Data is described 
using exponential terms, and the number 
of terms equals the number of 
compartments required. More complex 
models with bi-exponential and tri-
exponential equations incorporate two 
and three compartments, respectively [2, 
3]. 
1.2 POPULATION MODELING 
1.2.1 Introduction 
In PPK there are several parametric and nonparametric methods for estimating the 
parameters. Parametric methods have the ability to separate inter-individual, intra-individual 
and assay error. The weakness of this method is that it lacks mathematical consistency, and 
that it makes assumptions about the shape of the parameter distribution. Nonparametric 
methods on the other hand make no assumptions about the shape of the parameter 
distribution and can therefore detect possible subpopulations with other distributions. It is 
also mathematically consistent, but it does lack a feature to distinguish the various sources of 
variability. A few of the methods discussed here are the naïve approaches, the standard two-
stage approaches and the mixed effects mode [9, 10]. 
Figure 2. 2-compartment model with 
designated rate constants 
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1.2.2 Naїve pooled data approach 
The naïve pooled data (NPD) approach as proposed by Sheiner and Beal [11], is a method in 
which all data gathered from every individual are recognized as data coming from only one 
unique individual. The NPD approach is a general approach that can incorporate routine 
pharmacokinetic data, nonstandard data and experimental data. This simple approach is 
widely applicable, though the drawback is that it may give misleading parameter estimates. 
Since all data is recognized as coming from only one individual, the reference to individual 
data is lost and all sources of inter-individual variability are lost. There will not be provided 
any estimates of the dispersion of parameters in the population, only mean parameter 
estimates. Another drawback that needs to be addressed with this approach is imbalance, 
which occurs when some individuals provide more observations than others [5, 9]. 
1.2.3 Standard two-stage approach 
The standard two-stage (STS) approach is well known and widely used for more than 30 
years, because of its simple method for pooling individual estimates of PK parameters. The 
downside is that it requires large numbers of plasma samples to be obtained from each 
participant in the studies, i.e. data rich situations. The minimum is at least one plasma 
concentration data point per parameter estimated. As the name indicates, the population 
parameter estimates are obtained in two stages. In the first stage, each subject’s data are 
fitted separately, and from this the individual parameters are estimated using nonlinear 
regression. Also obtained from this step are the correlation and covariances between 
parameters in each patient. Then in the second stage, the parameters across the individuals 
are obtained. These include descriptive summary statistics, such as mean parameter 
estimates, variance and covariance. This approach usually gives unbiased mean parameter 
estimates, but have a tendency to overestimate the random effects. By weighting individual 
data according to quality and quantity, bias may be corrected and the STS approach can be 
improved [5, 6, 9, 10, 12]. 
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1.2.4 The nonlinear mixed-effect model approach 
Earlier attempts at modeling and estimating inter-individual pharmacokinetic parameter 
variability often neglected difficulties such as data imbalance, sparse data, and subject-
specific dosing history. Sheiner et al. [7, 11, 13-16] were the first to attempt to include these 
difficulties arising from data of patients receiving therapy. This is said to be the first true 
population modeling program. The data per individual used in this approach is usually of a 
limited number, and collected under less restrictive conditions. This approach can handle as 
few as one sample per patient. Observational individual PK data tend to be sparse, 
unbalanced and fragmentary, and because the resulting data sets are too small to separately 
estimate the PK parameters for each subject, the STS approach must be excluded. Like the 
NPD approach, nonlinear mixed-effect modeling analyzes data from all the individuals 
simultaneously. The difference is that the inter-individual random effects structure is 
included during nonlinear mixed-effect modeling. The population mean values derives from 
fixed effects, and the variability within the population derives from random effects 
parameters. This method is well known to give PPK parameters with less bias 
(overestimation) than the other methods [5, 9, 10]. 
1.3 MAXIMUM LIKELIHOOD APPROACH 
Estimation of the parameters in a model is most often done with the maximum likelihood 
approach, by minimizing the -2 log likelihood (-2LL)-function. -2 log likelihood is given by 
the following equation: 
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where Y is the measured observation, Yˆ  is the prediction of that observation by the model, 
and 2σ  is the variance of the model. The second part of the equation: 
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 is sometimes called the “extended least squares” objective 
function, and from this the objective function value (OFV) can be obtained. To minimize 
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-2LL the effort needs to be directed towards this second part, since )2log( pin  is a constant. 
Thus to minimize -2LL means that parameter estimates are chosen to maximize the 
probability of data under the model written as a function of the model parameters. This 
reveals the set of parameters that is more probable than any other set of parameters, as the 
best. The likelihood ratio test can therefore test for statistical significance between two or 
more models. Statistical significance is restricted under a given set of probability and degrees 
of freedom. It is however important to point out that the model with the lowest OFV is not 
necessarily the best model. Further, OFV cannot be used to compare different datasets. The 
choice of which model to be used must be justified by a better fit than the other models, 
especially when using more complex models. In a clinical setting the choice for model often 
falls on a fast and reliable model, even though it may not be statistically better [7, 9, 17]. 
1.4 NONMEM  
1.4.1 Background 
NONMEM was the first modeling program designed to analyze large amounts of PK data 
using nonlinear mixed-effect modeling. By utilizing first-order (FO) Taylor series expansion 
with respect to the random effect variables iη  and ijε , the program obtains linearity of the 
model in the random effects. From the following equation: 
ijiijij xfy εηφ += ),,(  Equation 2 
the j-th measurement in the i-th subject of the population can be obtained. φ  refers to the 
inter-individual parameter value estimates. iη  and ijε  are independent, normally distributed 
with zero means and variances Ω  and 2σ , respectively. By minimizing the term -2LL, the 
maximum estimates of population parameters θ ,  Ω  and 2σ  can be obtained as follow: 
))()())(log(det(2 1
1
iii
T
ii
N
i
i EyCEyCLL −−+=−
−
=
∑  Equation 3 
This is the most widely used approach in PPK, and is called the FO method [9]. 
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NONMEM has two alternative estimation methods: the first-order conditional estimation 
(FOCE) method and the Laplacian method. FOCE as the name indicates uses Taylor series 
expansion with the parameter values distributed about conditional estimates (empirical 
Bayesian estimates) of the inter-individual random effects rather than zero. The Laplacian 
method use second-order expansion [9]. 
1.4.2 Modeling with NONMEM 
NONMEM requires two specific files to be created by the user for modeling. One is the input 
file, which contains the data for describing the PK parameters, and the control file, which 
contains the model and parameter specifications [7]. 
Population modeling with NONMEM means that besides describing the PK parameters for 
the population, inter-individual and residual variability also needs to be described. An 
exponential statistical model for describing PK parameter inter-individual variability is 
expressed as: 
)( ijTVjij ExpPP η×=  Equation 4 
In this equation ijP  is the j-th basic PK parameter for the i-th individual. TVjP  is the typical 
value of the j-th population parameter. The typical value of a parameter is the population 
estimate of that parameter, usually the mean. ijη  is a random variable for the i-th individual 
in the j-th parameter distributed with a mean of  0 and variance of ijω  [18]. 
Residual variability can be described by a number of models: additive models, proportional 
(CCV; Constant Coefficient of Variation) models, exponential models, power function 
model, and combined additive and proportional model (slope-intercept model). Not all will 
be detailed in this thesis. More on this topic can be found in “NONMEM Workshop - Basic 
Concepts” by Shafer et al. [7]. 
The additive error model is described with the following equation: 
1ˆ ε+= YY  Equation 5 
The additive error model is described with the following equation: 
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( )11ˆ ε+×= YY  Equation 6 
The combined model describes the residual variability with the following equation: 
( ) 211ˆ εε ++×= YY  Equation 7 
In equation 4-6 Y  is the observed concentration,Yˆ  is the predicted concentration, and the 
randomly distributed terms 1ε  and 2ε  have zero mean and variances 1σ  and 2σ , 
respectively [18, 19]. 
1.5 CYCLOSPORIN A  
1.5.1 History of Cyclosporin A 
Cyclosporin A (CsA) was first discovered through screening of lower fungus extracts. Active 
metabolites from the fungus Cylindrocarpon Iucidum booth showed mild antifungal activity 
and antibody depression in mice. Oral administration of the drug in mice significantly 
depressed the appearance of plaque-forming cells and produced an obvious dose-dependent 
inhibition of haemagglutinin. Skin graft rejection in mice was considerably delayed by CsA. 
Isolation of the active principle revealed a hydrophobic cyclic polypeptide of 11 amino acids 
(undecapeptide) with a molecular weight of 1202.06. Soil samples collected from Norway in 
March of 1970 showed that the fungus Tolypocladium inflatum also contained CsA. This 
fungus was originally classified as Trichoderma polysporurn (Link ex Pers.) Rifai. In 1972 
CsA proved to have powerful immunosuppressive properties. Since then much research has 
been performed on the subject [20-23]. 
1.5.2 Applications and mechanism of action 
Cyclosporin A has been a cornerstone of solid organ transplantation since its introduction to 
the market in the early 1980’s, and is a major part of the success of immunosuppression in 
the clinical setting [18, 24]. CsA acts by forming a complex with the intracellular protein 
cyclophilin (an immunophilin), and this complex inhibits calcineurin. This will hinder the 
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activation of various transcription factors and ultimately lead to inhibition of interleukin-2 
synthesis and decrease the proliferation and function of T cells. The mechanism of action of 
CsA is partially selective in that it suppresses T cells while to some extent spares B 
lymphocyte activity. CsA will therefore permit a better response to infections than other 
immunosuppressive drugs [1, 25]. 
1.5.3 Known problems with Cyclosporin A 
When administering immunosuppressive drugs to organ transplant recipients, it is crucial to 
obtain the optimal exposure of the drug. This will not only prevent acute rejection, but also 
prolong the survival of the grafts, the organs, and inevitably the patients, simultaneously by 
also minimizing the side-effects. Cyclosporin A is like many other immunosuppressive 
drugs, and has a narrow therapeutic window and large inter-individual variability. This 
applies particularly after oral administration, to which observations have shown great 
variability within the first 4 hours. With concentration levels below the therapeutic window 
there is a high risk of organ rejection, while concentration levels above the therapeutic 
window is associated with side effects like nephrotoxicity, infection, hepatotoxicity, and 
cancer. Highly variable drug exposure may over time lead to chronic nephropathy, due to 
renal vasoconstriction. Glomerular filtration rate (GFR, ml/min) will decrease and cause 
hypertension, which will alter renal prostaglandin biosynthesis. It may necessitate the 
withdrawal of CsA. There are also a number of drugs that are known to interact with CsA, 
and may either lead to a decrease or an increase in CsA blood levels. Due to these particular 
problems, there are few PPK studies dealing with CsA modeling, but on the other hand it is 
for such a drug PK really can make a difference if used clinically. Especially the absorption 
profile of CsA makes PK modeling very difficult [1, 18, 25-31]. 
1.5.4 ADME 
CsA may be administered by intravenous infusion or orally, for which the peak plasma 
concentration is obtained after ~3-4 hours. The absorption profile of CsA is characterized as 
flat and delayed, with a correlation between delay and peak width [1, 27]. 
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Bioavailability of CsA depends highly on the population studied, but will normally range 
from 30-60 % [24, 29, 32]. 
Highly lipophilic drugs such as CsA bind to tissue to a great degree and would therefore have 
a volume of distribution that exceeds the 42 L that make up the total volume of water in the 
body. Within whole-blood CsA will distribute highly to erythrocytes, and in a lesser degree 
to lymphocytes and granulocytes. CsA has a large Vd even though it is highly bound to blood 
cells and plasma lipoproteins [3, 24, 32].  
Metabolism of CsA to its approximately 30 metabolites is extensively by the cytochrome 
P450 system, in particular CYP3A4 in majority and also CYP3A5. It is also a subject and 
inhibitor for the ATP-binding cassette transporter protein, P-glycoprotein (P-gp, mdr-1 / 
ABCB1). The metabolic pathways of CsA are made up of Phase I biotransformation by CYP 
enzymes, which include oxidation, dealkylation, and hydroxylation. CYP3A and P-gp work 
in concert to hinder CsA access to the systemic blood circulation. P-gp by counter 
transporting CsA out of the enterocyte, i.e. efflux, and back into the gut lumen, makes CsA 
available once again for metabolism by the CYP enzymes. This cycle greatly enhances drug 
metabolism. As these systems are present in a large degree in the intestines and the liver, 
CsA is therefore subject to a large first pass effect, and hence have low oral bioavailability. 
Genotypical differences in CYP3A5 protein expression have proven to cause notable 
variations in CsA PK. Less consistent is the association between polymorphism of the mdr-1 
gene and CsA PK. Mutation in the mdr-1 gene may cause lower P-gp levels, which may 
decrease the dose requirement for CsA [3, 24, 33-38]. 
The biliary system is responsible for most of the elimination of CsA, and only 6 % of the 
metabolites are excreted renally. It is worth mentioning that the absorption of CsA requires 
an adequate flow of bile, so that CsA is also a part of enterohepatic recycling [24, 29, 30, 
39]. 
Half life of CsA varies to a great extent, with approximately 6.3 hours in healthy individual 
and to 20.4 hours in patients with serious liver complications [32]. 
Even though there are much literature on the matter of the PK and PD of CsA, there are still 
difficulties in predicting the disposition in specific individuals. The need for a population 
approach is evident when reviewing the many causes for variation [18]. 
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1.5.5 The need for therapeutic drug monitoring 
The causes for pharmacokinetic variability of CsA are complex and difficult to predict, 
which usually renders therapeutic drug monitoring (TDM) mandatory to maximize the 
immunosuppressive effects of CsA. The index most closely linked to the therapeutic effect 
and also the toxic effects, is thought to be the inter-dose area under the plasma concentration 
curve from 0 to 12 hours (AUC0-12). This monitoring approach is both time consuming and 
expensive, and rarely done in routine clinical practice. However, the optimal method for 
TDM is still debated, and blood level measurements are often performed either at trough 
level (C0), and/or 2 hours after dosing (C2). The downside to measuring single samples is of 
course less accurate drug exposure predictions. C2 measurements are believed to be better 
associated with AUC0-4, which is also considered a marker for toxic effects [24-28, 31, 40, 
41]. 
1.5.6 PK models of Cyclosporin A in litterature 
Findings in literature show that there have been many attempts to model the PK of CsA, and 
all have come to a different conclusion as of what is the PK population model that best 
describes this. Both 1- and 2-compartments are used in these different models, and different 
absorption methods have been used. For some models the Erlang distribution gave a good fit, 
while others used an absorption lagtime. In addition each study tested a wide range of 
covariates on their model [18, 28, 29, 34, 35, 41, 42]. It was therefore necessary to try out 
many different models in our search.  
1.6 GOALS 
The goal of this thesis is to make a PK population model for CsA, by using data gathered 
from previous clinical trials performed at the Department of Pharmaceutical Biosciences, 
School of Pharmacy, University of Oslo. The final model is then to be used in an add-on 
study to compare the effectiveness of TDM of CsA using NONMEM, against TDM using 
traditional clinical C2 monitoring. This add-on study will provide a real-time data assembly 
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and evaluation that can provide drug exposure safety monitoring. Results from this study will 
not be presented in this thesis. 
Specific goals for the thesis include testing different compartment models with different 
absorption and elimination profiles, screen for possible clinically relevant covariates that 
may improve the compartment model, and apply internal validation as well as external 
validation methods.  
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2 METHODS AND MATERIALS 
2.1 STUDY DESIGN AND POPULATION 
Data were obtained from 49 patients who received renal transplantation at Rikshospitalet 
University Hospital HF, Oslo, Norway. CsA (Sandimmun Neoral®, Novartis Pharmaceuticals 
Corporation, Switzerland) was administered orally twice daily in soft gelatin capsule 
formulation, along side other routine protocol medication.  
The data were obtained from three separate prospective clinical trials, so there were 
variations in the amount of information gathered. The medical records contained date, time, 
transplantation date, CsA dosage, CsA blood concentration, gender, age, weight, height, 
serum creatinine, urea, and concurrent medication. A full PK population sampling design 
was used to allow blood samples to be drawn at various times. This allowed estimation of 
PK parameters and explanation of variability [6]. A total of 1027 drug concentration 
monitoring data points was gathered.  
Patients 1-20 were from the SUPER-CsA study [43]. This was a single centre prospective 
pilot study following patients from 0 to 17 weeks post-transplantation, with measurements 
made sporadically at trough level (C0) and 2 hours after CsA administration (C2). Nine of 
these patients (patients 7-12, 14 and 18-19) had a 12-hours pharmacokinetic profiling done 
once during the study period. During the 12-hours, measurements of whole-blood CsA 
concentrations were made at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours after CsA 
administration. All of the data gathered from the patients were included in the model. 
Analyses of the whole-blood CsA concentrations were performed using the CEDIA 
Cyclosporine PLUS assay (Cloned Enzyme Donor Immunoassay; Microgenics Corporation, 
Fremont, CA) as described by Falck et al. [43], except the 12-hours PK-profiling whole-
blood samples which were analyzed for CsA concentrations with a validated LC-MS/MS 
method [44, 45].  
Patients 30-37 were from the MIMPARA study [45], which is an interaction study between 
Cinacalcet® and immunosuppressive drugs. 13 whole-blood plasma concentration 
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measurements (0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10 and 12 hours after administration) were 
performed during a 12-hours pharmacokinetic profiling between 3-10.4 weeks after renal 
transplantation. Only CsA data from before Cinacalcet® administration were used in this 
model development. Whole-blood samples (heparine vacutainers) were immediately frozen 
and stored at −30◦C until analyzed for CsA concentrations with a validated HPLC-MS/MS 
method [45]. 
The remaining patients (51-65 and 67-72) were from a CsA study performed to find any 
possible effect of age on the PK of CsA [44]. These patients also had a 12-hours PK-
profiling performed between 2-9 weeks after renal transplantation. Whole-blood CsA 
concentration were measured at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 hours after 
administration of CsA. The whole-blood samples were analyzed for concentrations of CsA 
using a validated LC-MS/MS method [44]. 
Whole-blood samples for the 12-hours PK-profiling were analyzed at both the study center, 
Rikshospitalet University Hospital HF, and by the Department of Pharmaceutical 
Biosciences. While whole-blood samples taken sporadically were only analyzed by 
Rikshospitalet University Hospital HF. Analysis results showed that there was significant 
inter-laboratory variability. This may be the result of the different analysis methods. All CsA 
concentrations analyzed by the Department of Pharmaceutical Biosciences were therefore 
adjusted to the correct concentration, as defined by Rikshospitalet University Hospital HF, 
with the following equation: 
88.0×=DPBRH  Equation 8 
where RH  is the adjusted concentration according to Rikshospitalet University Hospital HF, 
and DPB  is the concentration obtained from analysis performed by the Department of 
Pharmaceutical Biosciences. This equation was obtained from correlation of concentrations 
measured at both laboratories in the three studies. [43-45] 
As data was gathered at various times, it was in a sense no missing data points to speak of. 
There was therefore no need to impute any data points that might have influenced the bias.  
The exact time of each blood sample was written down, except for some of the samples 
taken sporadically as mentioned above. All data points were included in the input file for 
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NONMEM. Sporadic measurements were coded for C0 as 06.00 hours for morning doses and 
20.00 hours evening doses, while C2 was coded as 08.00 hours for morning doses and 22.00 
hours evening doses. 
2.1.1 Cofactors influencing Cyclosporin A 
Before choosing which cofactors that is relevant and that need to be studied, it is important 
to distinguish between clinically relevant and statistically significant covariates. There needs 
to be a rationale behind the choices that are made [5]. 
Cofactors chosen to be studied were based on findings in literature and clinical findings. 
Weight (kg), creatinine clearance (ml/min.), type 1 diabetes (1=non-diabetic; 2=type 1 
diabetes), age (years), gender (1=male; 2=female), height (m), post-transplantation time 
(weeks), steroid dose (mg), body mass index (BMI) (kg/m2), CYP 3A5 genotype (1=*1/*3; 
3=*3/*3), and lean body mass (kg), were screened to uncover any possible influence on the 
proposed PK population model [26-28, 35, 40, 46, 47]. Lean body mass was calculated from 
the height and weight of the patients with the following equations [48]: 
Male;  5336.2933929.032810.0... −+= HWMBL  Equation 9 
Female; 2933.4341813.029569.0... −+= HWMBL  Equation 10 
Creatinine clearance was calculated using the Nankivell equation [49]: 
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Saint-Marcoux et al. [26] encoded post-transplantation time as a factor for variability in their 
population model for CsA. They divided the time frame into three periods, < 2 weeks, 
between 2 weeks and three months, and > 3 months. In our model we chose to code post-
transplantation time as a continuous covariate with a linear and proportional model and also 
as a categorized continuous covariate, divided into < 2 weeks and ≥ 2 weeks. 
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Table 1. Patient demographics 
    
Value Mean Range 
Total number of patients 49    
Number of patients with type 1 diabetes 9    
Age (years) 
 55.0 21.0 78.6 
Weight (kg) 
 78.5 49.0 106.5 
Height (m) 
 1.76 1.53 1.92 
Body mass index (kg/m2) 
 24.9 18.9 35.2 
Lean body mass (kg)* 
 55.7 36.4 66.5 
Gender; 
    
 Male 33    
 Female 16    
CYP 3A5 genotype;     
 *1/*3 6    
 *3/*3 43    
Post-transplantation time (weeks) 
 5.1 0.0 17.0 
Total daily steroid dose (mg) 
 23.2 0.0 80.0 
Creatinine clearance (ml/min.)*2 
 71.35 6.78 162.50 
Cyclosporine; 
    
 Dose (mg/12 hours) 
 216 25 600 
 
Observed whole-blood  
concentration (ng/ml) 
1056 30 3240 
 Total number of samples 1027    
  
Average number of 
samples per patient 
21.0 
      
*
 calculated using equation 9 and 10 
*
2
 calculated using the Nankivell formula 
(equation 11)     
 
A factor that might influence the overall result of model building is the fact that all the 
patients received their steroid dose in the form of orally administered prednisolone, with the 
exception of patient no. 2 that started out on oral prednisolone, and later switched over to i.v. 
Solu-Medrol®. The significance of this variable was not tested in this model. 
2.2 BUILDING THE POPULATION MODEL 
The pharmacokinetic population modeling was done with NONMEM (version VI; 
GloboMax LLC, Hanover, MD, USA) and the graphical diagnostics was obtained by using 
the program R (http://www.r-project.org/) and Microsoft Office Excel 2003©. The model 
building process is made up of different steps.  The first step before building the population 
model was to compile all of the data available into the input file for NONMEM to read 
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(Appendix 7.1). Data from patient charts was inserted into an input file and double checked 
against information available at the study center to detect and correct any possible errors.  
The second step was to create and test control files with different compartment models with 
first-order elimination, and include first- or zero-order absorption, with or with out 
absorption lagtime. The number of compartments ranged from one to three. Criteria for 
choice of model to be used in the next step included the model that gave the best statistical 
result, i.e. the lowest OFV value, had a short run time, and also the model that gave the best 
stability during testing [7, 19]. 
The parameters used to describe the compartment models includes clearance (CL), central 
volume (VC), peripheral volumes (VPn), intercompartmental clearances (Qn), absorption rate 
constant (ka), rate constant between the central and peripheral compartments (kCP, kPC), and 
absorption lagtime (ALAG) [19]. Also tested was the Erlang distribution, because of the 
flexibility in modeling flat or delayed absorption profiles. The Erlang distribution is a special 
form of gamma distribution and describes a right skewed absorption lag. More specifically 
the Erlang distribution is an analytical solution for a number of “n” compartments linked 
together with the same transfer rate constant, ktr. These theoretical Erlang compartments are 
positioned between the depot and the central compartments of the population model [26, 27]. 
             kcp 
 
 
 ktr  ktr  ktr  ktr  ktr  ktr → 
 1 → 2 → 3 → 4 → 5 → 6 → ← 
 
 
VC 
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VP 
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Figure 3. This illustrates a 2-compartment model with an Erlang distribution 
[27]. 
The rate of exit, ( )timef , from the Erlang compartments can be described by the following 
equation:  
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)exp(1
−
×−×
=
−
n
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nn
tr
 Equation 12 
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Determining the number of sequential Erlang compartments was done by using the criteria 
that the number of compartments was increased until no improvement or deterioration of the 
model performance could be seen. The same number of Erlang compartments, n, is then set 
to all the patients in the data set [26]. ktr would in an Erlang model replace ka of ordinary 
compartment models.  
Unlike absorption lagtime which just gives a delay in absorption, the Erlang distribution 
models an increasing transition for the absorption. This may create a more realistic model of 
the absorption process for drugs such as CsA. 
During the model building process the error model used to describe the residual variability 
was the combined additive and proportional model. While an exponential error model was 
used to describe the inter-individual variability. These choices for error models were based 
previous experience and findings in literature [27, 50]. 
NONMEM provides several estimation methods, and the ones utilized in during model 
building were FO and FOCE  [28]. 
The NONMEM program relies on the estimation of parameter through statistical significance 
of the maximum likelihood approach. By comparing the resulting OFV the different models 
can be compared. The criterion set for improvement in fit is a drop in OFV > 3.84 [7]. 
2.3 ANALYZING FOR COVARIATES 
2.3.1 Introduction to methods used 
The third step when building a PPK model is to establish the relationship between the model 
parameters and the covariates. The covariates are patient specific variables that can explain 
parameter variability. Covariates are divided into continuous covariates and categorical 
covariates. In modeling continuous covariates are usually centered in the normal population 
model, while categorical covariates are handled by one or more IF / ELSE statements [51, 
52]. 
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The covariate model is built in a stepwise manner using forward inclusion - backward 
deletion. In the first step, the start model is the basic model without covariates. To this start 
model, all possible parameter-covariate combinations are tested in turn. The number of these 
combinations is often large, for example 11 covariates with 6 parameters would give a total 
of 66 combinations. These combinations would then be modeled with different covariates 
equations. If on average there are 5 equations for each combination, it would result in 330 
different control files that would need to be run through NONMEM. It is safe to say this is a 
time consuming process [18, 51-54]. 
The covariates were tested with the following equations [7]: 
Linear model: 
valueariatevcoTV ppop ×+= 1θθ  Equation 13 
valueariatevcoTV ppop ×−= 1θθ  Equation 14 
Proportional model: 
valueariatevcoTV ppop ×= θ  Equation 15 
valueariatevcoTV ppop θ=  Equation 16 
where popTV  is the typical value of the population estimate, pθ  is the individual parameter 
estimate, and 1θ  is the factor contributed by the covariate. In addition, the continuous 
covariates in the linear model were centered to their mean value [7]. 
Linear model: 
( )valueariatevcomeanvalueariatevcoTV ppop −×+= 1θθ  Equation 17 
( )valueariatevcomeanvalueariatevcoTV ppop −×−= 1θθ  Equation 18 
An example is given with the following equation: 
( )46.87/2 72 −×+= BWFV θθ  Equation 19 
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This equation represents the relationship between V2/F and bodyweight (BW) in kg. V2/F is 
the population mean value of V2/F in liters, 2θ  is the V2/F value of a median patient 
weighing 78.4 kg, and 7θ  is the difference in V2/F per kg BW, with the population average 
taken into consideration [26]. 
The categorical covariates were handled by the following IF / ELSE statements [7]: 
Type 1; 
[ ] [ ]( )
[ ]
[ ]
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In addition to these models, the following model was decided to be tested: 
( )100/11 valueriatevacoTV ppop +×+= θθ  Equation 22 
( )100/11 valueriatevacoTV ppop +×−= θθ  Equation 23 
The inclusion criteria are based on the likelihood ratio test, and rely on improvement in fit. 
During inclusion of covariates, a reduction in OFV > 3.84 is considered significant at p < 
0.05, and a reduction > 6.63 is considered significant at p < 0.01. Covariate combinations 
that give a significant drop in OFV are included in the model for the next step. The next step 
involves including all significant covariates into one model, the full model. From this full 
model, one covariate is removed at a time. This process is called backwards deletion. A 
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stricter criterion is used during backwards deletion, and requires significance at p < 0.05, i.e. 
an increase in OFV of > 6.63. An increase in OFV > 10.9 is considered significant at p < 
0.01. When no more covariates can be excluded from the model according to the criteria, 
then the final model is established. The final model would then only include the covariates 
that proved to be statistically significant [26, 30, 51, 52, 54]. Covariates were assumed to be 
constant within an individual for the sake of simplicity [4]. 
To perform backwards deletion where one covariate is removed at a time from the full 
model, THETA-value of the linear models are fixed at 0, THETA-value of the type 1 IF / 
ELSE statements (Equation 16) are fixed at 1, and for the other models the covariate was 
removed entirely from the control file. 
2.4 CRITERIA FOR CHOICE OF MODEL 
The decision for what would be the final structural model was made considering 1) the 
objective function value (OFV), 2) the residual variability, 3) correlation and regression 
analysis between predicted concentration (IPRE/PRED) and observed concentration (DV), 4) 
the aspect of the weighted residual (WRES, residuals weighted by the standard deviation) 
plots, 5) graphical analysis of concentration-time curves, and 6) clinical applicability [26, 28, 
30]. 
2.5 VALIDATING THE MODEL 
2.5.1 Internal validation 
2.5.1.1 Examining the predictive performance of the population model 
A PK population model needs to show high goodness of fit, good stability, reliability and 
predictive performance. Following FDA recommendations [6] data-splitting was used to 
randomly divide the full dataset into 10 subsets, each containing ~ 90 % of the patient data. 
The data were randomized into 10 subgroups by using a combination of the “Random 
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Sequence Generator” and the “Random Integer Generator” on the website 
http://www.random.org [55]. 
Table 2. Subgroups after data-splitting 
Patients excluded Subgroup 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
A 2 8 32 54 33 
B 3 17 60 61 53 
C 11 4 34 72 67 
D 13 10 36 69 57 
E 12 5 55 68 37 
F 15 7 59 52  
G 20 19 65 30 64 
H 18 6 70 71 58 
I 14 1 31 51 56 
J 9 16 63 62 35 
 
The subsets with the included patients were then analyzed individually using the final model. 
Parameter estimates obtained were then compared to those obtained from the full data set. 
The parameter estimates from each of the subsets were also used to predict the CsA 
concentrations of the data subsets containing the remaining ~10 % of the patients. This was 
done by removing the observed concentrations from the ~10 % data subset and running 
NONMEM with the commands, “MAXEVAL=0” and “posthoc” in the $ESTIMATION 
step. Four different data sets were created for each subgroup. For the first data set all the 
observed concentrations were included, for the second data set no observations were 
included, for the third data set only the first observed concentration was included, and for the 
last data set the first and second observed concentration was included. In addition the 
objective function value was calculated when applying the parameters obtained from the 10 
subsets with included patients on to the full data set. The OFVs were compared to that 
obtained from the final model. The intent was to examine the validity of the parameter 
estimates, the robustness of the final model, and to evaluate the predictive performance of 
the final model [6, 18, 26, 28, 50, 56, 57]. 
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To calculate the difference between the observed and the model-predicted concentrations, the 
prediction errors on concentration was used. Mean prediction error (ME, ng/ml) was 
calculated as a measure of bias, and mean squared prediction error (MSE, (ng/ml)2) and root 
mean squared error (RMSE, ng/ml) was calculated to assess the precision. Predictive 
performance was also assessed by standardized prediction error (SPE). 
∑
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where ObsC  is the observed concentration and edCPr  is the predicted concentration. CpredSD  is 
the standard deviation of the predicted concentration and the total number of observations in 
the validation group is given by the number n [5, 18, 51]. 
Besides data-splitting there is another technique to internally validate a model, which is 
called resampling. There are two ways to perform resampling [5, 6]: 
• Cross-validation: a repeated data-splitting validation, where fewer data points are 
discarded during the estimation process. 
• Bootstrapping: using the entire dataset, it is useful for datasets with limited sizes [57]. 
These techniques were not utilized and will therefore not be discussed further. 
2.5.2 Confidence interval 
Confidence intervals (standard errors) for the parameters can be estimated using a 
nonparametric technique called “The Jackknife”. The procedure entails excluding parts of 
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the data one by one, in this case one patient is excluded from the dataset at a time, which 
produces a total of 49 Jackknife data input files. Following this, each Jackknife data set is 
tested with the final model. Parameter estimates from these NONMEM runs are used to 
calculate the confidence interval. When estimating standard errors and bias, bootstrapping 
might perform better, but the Jackknife has the advantage of requiring less computation [5, 
53, 58, 59]. 
2.5.3 External validation 
The external validation process is where we apply the developed model on to a new set of 
data from another study [57]. The external data not used to develop the model will provide 
estimation of the actual prediction error, as opposed to the apparent prediction error 
obtained when estimation is done through internal data-splitting [60].  
The external data set comprised of 10 anonymous patients who received renal transplantation 
at Rikshospitalet University Hospital HF, Oslo, Norway. All 10 patients were given routine 
treatment according to protocol, with C0 and C2 sampling performed according to 
Rikshospitalet University Hospital HF’s protocol. This provided 215 CsA concentration 
measurements. The whole-blood samples were collected between 0-12 weeks after renal 
transplantation. Patient demographics relevant to the model were also provided in the 
patients charts. Whole-blood samples were analyzed for CsA concentrations using the 
CEDIA Cyclosporine PLUS assay (Cloned Enzyme Donor Immunoassay; Microgenics 
Corporation, Fremont, CA) as described by Falck et al. [43] 
Data sets were created with all the observed concentrations, no observed concentrations, the 
first observed concentration, observed concentrations from the first week or observed 
concentrations from the second week. The individual predicted concentrations from these 
five data sets were compared to the actual observed concentrations. The same prediction 
errors used for predictive performance were calculated (equation 24-27). 
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Table 3. External validation patients demographics 
    
Value Mean Range 
Total number of patients 10    
Number of patients with type 1 diabetes 1    
Age (years) 
 59.2 35.0 77.0 
Weight (kg) 
 67.4 40.0 102.0 
Height (m) 
 1.68 1.53 1.87 
Body mass index (kg/m2) 
 23.0 16.2 30.5 
Lean body mass (kg)* 
 50.3 36.9 66.0 
Gender; 
    
 Male 4    
 Female 6    
CYP 3A5 genotype; 
    
 *1/*3 NA    
 *3/*3 NA    
Post-transplantation time (weeks) 
 4.7 0.0 12.0 
Total daily steroid dose (mg) 
 17.1 10.0 50.0 
Creatinine clearance (ml/min.)*2 
 62.78 4.83 125.29 
Cyclosporine; 
    
 Dose (mg/12 hours) 
 154 50 400 
 
Observed whole-blood  
concentration (ng/ml) 1098 85 2595 
 Total number of samples 215    
  
Average number of 
samples per patient 
21.5 
      
*
 calculated using equation 9 and 10 
*
2
 calculated using the Nankivell formula 
(equation 11)     
 
The appropriateness of the final model will also be reviewed by comparing dosage strategies. 
Real-time data assembly and evaluation from an add-on study gives the opportunity to 
compare the NONMEM based TDM against clinical TDM. The results from this add-on 
study will start during the 2nd quarter of 2008 and will therefore not be presented in this 
thesis. 
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3 RESULTS 
3.1 MODEL BUILDING RESULTS 
Model development was a time consuming task were many different models had to be 
screened to evaluate the appropriateness of the model compared to the CsA data provided. 
The screening process was performed while keeping in mind the criteria mentioned in 
paragraph 2.4. Inclusion of the Erlang distribution proved to be time consuming and was 
therefore only tested on the most promising model, which was the 2-compartment model.  
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Table 4. Results from model screening 
Residual variability Compartment 
model 
Model  
specifications 
Objective  
function  
value 
Proportional  
(%) 
Additive  
(ng/ml) 
Run time 
(hh:mm:ss) 
1-compartment 1. order  
absorption 13035.80 36.19 0.01 00:01:21 
1-compartment 1. order  
absorption  
w/ lagtime 
12807.03 31.94 2.69 00:04:40 
2-compartment 1. order  
absorption 12805.39 31.40 6.34 00:11:32 
2-compartment 1. order  
absorption  
w/ lagtime 
12403.00 24.86 4.83 00:17:02 
2-compartment 1. order  
absorption  
w/ lagtime &  
covariates 
12088.5 19.18 5.38 00:24:36 
2-compartment 0. order  
Absorption 
 w/ lagtime 
12954.06 34.93 0.98 00:10:24 
2-compartment 1 Erlang  
compartment 12614.71 27.46 27.42 04:46:17 
2-compartment 2 Erlang  
compartment 12512.24 25.86 24.76 17:03:55 
2-compartment 3 Erlang  
compartment 12469.43 25.24 21.12 10:34:43 
2-compartment 4 Erlang  
compartment 12439.46 24.25 29.19 26:28:56 
2-compartment 5 Erlang  
compartment 12816.19 31.94 0.37 03:36:47 
2-compartment 6 Erlang  
compartment 12430.74 24.23 23.04 83:20:34 
2-compartment 7 Erlang  
compartment 12434.28 24.29 23.24 98:13:25 
3-compartment 1. order  
absorption 12776.76 31.62 3.16 00:51:24 
3-compartment 1. order  
absorption  
w/ lagtime 
12457.45 25.16 35.07 01:10:49 
 
Applying elaborate functions to the control file further complicates the model, which can be 
seen by the steady increase in run time when functions such as lagtime, covariates and Erlang 
distribution is added (Table 4). The upside of making an elaborate model is the fact that it 
better describes the data and to a certain point decreases the OFV. 
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Table 5. Parameter estimates of the models during preliminary screening 
Q/F V/F Compartment 
model 
Model  
specifications 
CL/F 
1 2 C P1 P2 
ka ;  
ktr 
ALAG 
1-compartment 1. order  
absorption 23.4 - - 138 - - 1.6 - 
1-compartment 1. order  
absorption  
w/ lagtime 
23.2 - - 145 - - 4.79 0.454 
2-compartment 1. order  
absorption 23.3 18.3 - 54.8 277 - 0.615 - 
2-compartment 1. order  
absorption  
w/ lagtime 
26.6 19.2 - 80.3 343 - 1.86 0.452 
2-compartment 1. order  
absorption  
w/ lagtime &  
covariates 
26.1 20.5 - 77.7 342 - 1.88 0.452 
2-compartment 0. order  
absorption  
w/ lagtime 
22.1 186 - 1.15 120 - 0.32 0.33 
2-compartment 1 Erlang  
compartment 24 25.2 - 62 331 - 1.49 - 
2-compartment 2 Erlang  
compartment 24.8 29.9 - 66.5 289 - 2.5 - 
2-compartment 3 Erlang  
compartment 24.7 27.4 - 82 286 - 3.93 - 
2-compartment 4 Erlang  
compartment 23.6 24 - 91.7 389 - 5.58 - 
2-compartment 5 Erlang  
compartment 23.6 23.1 - 145 215 - 8.23 - 
2-compartment 6 Erlang  
compartment 23.9 24.5 - 95.2 377 - 8.14 - 
2-compartment 7 Erlang  
compartment 23.8 23.9 - 96.5 366 - 9.59 - 
3-compartment 1. order  
absorption 21.8 10.1 11 81.1 25.2 498 0.897 - 
3-compartment 1. order  
absorption  
w/ lagtime 
23.7 10.1 21.3 50.6 54.6 187 1.2 0.447 
Abbreviations; CL = clearance, Q1 = intercompartmental clearance for peripheral compartment 1, 
Q2/F = intercompartmental clearance for peripheral compartment 2, VC = central volume, VP1 = 
peripheral volume 1, VP2 = peripheral volume 2, ka = absorption rate constant, ktr = Erlang transfer 
rate constant, ALAG = absorption lagtime, F = bioavailability 
Parameter values estimated from the different compartment models show consistency and are 
comparable to parameter values listed in other studies, such as those of Bourgoin et al.[41], 
Fanta et al. [29], Hesselink et al. [34], Irtan et al. [28] and Wu et al.[18]. 
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3.1.1 Graphical comparison of the models 
Patient no. 70 was chosen to demonstrate the graphical process of model building. The 12-
hours PK-profiling was plotted and compared between the different PK population models.  
Visual analysis based on structure and fit of the plot was included in the decision for model 
development. Improvement of individual predicted concentrations was weighted more than 
improvement of population predicted concentration at this point in model development. 
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Figure 4. 12-hours PK-profiling of patient no. 70 with the different preliminary models 
(x = Time (h); y = Plasma concentration (ng/ml))  
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3.2 ANALYZING FOR COVARIATES 
The fixed-effects parameters estimated for the final 2-compartment model were CL/F (θ1), 
Q/F (θ2), VC/F (V1/F, θ3), VP/F (V2/F, θ4), ka (θ5), and ALAG (θ6). In the screening process 
all the covariates were tested individually on each parameter with every possible equation for 
the covariate in question. All the positive covariates were then double checked for 
significance in the second screening, before chosen for backwards deletion. 
Table 6. The significant covariate CYP 3A5  
Covariate Parameter Model OFV ∆ OFV P 
CYP 3A5 CL IF C3A5=1 TVCL=θ(1)  
/ ELSE TVCL=θ(7)  
12398.92 4.08 < 0.05 
 V2 IF C3A5=1 TVV2=θ(4)*θ(7)  
/ ELSE TVV2=θ(4)*θ(8) 
12362.20 40.80 < 0.01 
 
CYP 3A5 as a covariate did give significant change in OFV. It was however not included in 
the final model because it did not fit in with the clinical setting of the proposed add-on study. 
All the significant covariates that were chosen for further testing with backwards deletion are 
presented in table 7, and all the covariates that showed significance according to the criteria 
set for backwards deletion are presented in table 8. These were then included in the final 
model.  
Every covariate tested gave at least one significant change in OFV, expect for type 1 
diabetes. Initial screening showed some change, but no significance was seen. A more 
elaborate coding for diabetes may be needed as some patients had type 2 diabetes before 
receiving renal transplantation and some patients developed type 2 diabetes after receiving 
transplantation. The impact of this covariate was not tested for this model. 
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Table 7. Significant covariates after forward inclusion 
Covariate Parameter Model OFV ∆ OFV P 
Age V2 TVV2=θ(4)-θ(7)*(1+AGE/100) 12398.90 4.10 < 0.05 
BMI Q TVQ=θ(3)+θ(7)*(BMI-24.86) 12396.35 6.65 < 0.01 
  V2 TVV2=θ(4)+θ(7)*BMI 12352.59 50.41 < 0.01 
Creatinine CL V1 TVV1=θ(2)-θ(7)*(CRCL-71.35) 12362.67 40.33 < 0.01 
  V2 TVV2=θ(4)-θ(7)*(1+CRCL/100) 12397.35 5.65 < 0.05 
Gender CL IF GEN=1 TVCL=θ(1)*θ(7)  
/ ELSE TVCL=θ(1)*θ(8) 
12395.43 7.57 < 0.01 
  KA IF GEN=1 TVKA=θ(5)*θ(7)  
/ ELSE TVKA=θ(5)*θ(8) 
12391.29 11.71 < 0.01 
  V1 IF GEN=1 TVV1=θ(2)*θ(7)  
/ ELSE TVV1=θ(2)*θ(8) 
12395.14 7.86 < 0.01 
  V2 IF GEN=1 TVV2=θ(4)*θ(7)  
/ ELSE TVV2=θ(4)*θ(8) 
12356.30 46.70 < 0.01 
Height KA TVKA=θ(5)-θ(7)*(HGHT-1.76) 12392.63 10.37 < 0.01 
  Q TVQ=θ(3)+θ(7)*(1+HGHT/100) 12398.81 4.19 < 0.05 
  V1 TVV1=θ(2)+θ(7)*(HGHT-1.76) 12396.90 6.10 < 0.05 
  V2 TVV2=θ(4)-θ(7)*HGHT 12397.02 5.98 < 0.05 
LBM CL TVCL=θ(1)+θ(7)*(LBM-55.74) 12394.07 8.93 < 0.01 
  V1 TVV1=θ(2)+θ(7)*(LBM-55.74) 12397.33 5.67 < 0.05 
Steroid dose CL TVCL=θ(1)+θ(7)*STER 12292.87 110.13 < 0.01 
  KA TVKA=θ(5)-θ(7)*(1+STER/100) 12303.79 99.21 < 0.01 
  V1 TVV1=θ(2)-θ(7)*(1+STER/100) 12397.74 5.26 < 0.05 
  V2 TVV2=θ(4)+θ(7)*STER 12398.90 4.10 < 0.05 
Post- 
transplantation 
ALAG IF TXT<2 TVALAG=θ(6)*θ(7)  
/ ELSE TVALAG=θ(6)*θ(8) 
12210.76 192.24 < 0.01 
time KA TVKA=θ(5)+θ(7)*TXT 12147.16 255.84 < 0.01 
 Q IF TXT<2 TVQ=θ(3)*θ(7)  
/ ELSE TVQ=θ(3)*θ(8) 
12179.73 223.27 < 0.01 
  V1 TVV1=θ(2)-θ(7)*TXT 12303.54 99.46 < 0.01 
  V2 TVV2=θ(4)-θ(7)*(1+TXT/100) 12398.98 4.02 < 0.05 
Weight V2 TVV2=θ(4)-θ(7)*WT 12396.91 6.09 < 0.05 
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Table 8. Significant covariates after backwards deletion 
Covariate Parameter Model OFV ∆ OFV P 
BMI V2 TVV2=θ(4)+θ(29)*BMI 11985.76 12.84 < 0.01 
Creatinine CL V1 TVV1=θ(2)-θ(21)*(CRCL-71.35) 12078.80 105.88 < 0.01 
Gender CL IF GEN=1 TVCL=θ(1)*θ(7)  
/ ELSE TVCL=θ(1)*θ(8) 
11989.95 17.03 < 0.01 
  KA IF GEN=1 TVKA=θ(5)*θ(15)  
/ ELSE TVKA=θ(5)*θ(16) 
12051.13 78.21 < 0.01 
  V1 IF GEN=1 TVV1=θ(2)*θ(9)  
/ ELSE TVV1=θ(2)*θ(10) 
12167.10 194.18 < 0.01 
  V2 IF GEN=1 TVV2=θ(4)*θ(13)  
/ ELSE TVV2=θ(4)*θ(14) 
11992.99 20.07 < 0.01 
Height KA TVKA=θ(5)-θ(30)*(HGHT-1.76) 11980.58 7.66 < 0.05 
  Q TVQ=θ(3)+θ(26)*(1+HGHT/100) 11986.33 13.41 < 0.01 
  V1 TVV1=θ(2)+θ(22)*(HGHT-1.76) 12096.86 123.94 < 0.01 
LBM CL TVCL=θ(1)+θ(20)*(LBM-55.74) 11980.77 7.85 < 0.05 
  V1 TVV1=θ(2)+θ(25)*(LBM-55.74) 11988.55 15.63 < 0.01 
Steroid dose CL TVCL=θ(1)+θ(19)*STER 12086.09 113.17 < 0.01 
  KA TVKA=θ(5)-θ(31)*(1+STER/100) 12076.88 103.96 < 0.01 
  V1 TVV1=θ(2)-θ(24)*(1+STER/100) 12042.40 69.48 < 0.01 
  V2 TVV2=θ(4)+θ(28)*STER 12005.42 32.50 < 0.01 
Post- 
transplantation 
ALAG IF TXT<2 TVALAG=θ(6)*θ(17)  
/ ELSE TVALAG=θ(6)*θ(18) 
11980.60 7.68 < 0.05 
time KA TVKA=θ(5)+θ(32)*TXT 12177.61 204.69 < 0.01 
 Q IF TXT<2 TVQ=θ(3)*θ(11)  
/ ELSE TVQ=θ(3)*θ(12) 
12094.28 121.36 < 0.01 
  V1 TVV1=θ(2)-θ(23)*TXT 11994.78 21.86 < 0.01 
Weight V2 TVV2=θ(4)-θ(27)*WT 12090.99 118.07 < 0.01 
 
OFV in the start model was 12403.00 and dropped to 11972.92 when all the significant 
covariates were added. After the backwards deletion the final model had an OFV of 
12088.50, which is highly significantly better than the start model. 
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3.2.1 Covariate analysis based on visual and graphical representation 
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—— Individual predicted concentrations 
– – –  Population predicted concentrations 
Figure 5. Comparison of start model to the final model in patient no. 70s full 
12-hours PK-profiling (x = Time (h); y = Plasma concentration (ng/ml)) 
Patient no. 70 showed the greatest improvement in fit after inclusion of covariates. When 
comparing the start model to the full covariate model it is clear that the population predicted 
concentrations are corrected according to the covariates. The peak concentrations are more 
accurate and no longer underestimated. 
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Figure 6. Plots showing the best (left) and worst (right) fits of the start model 
for PK-profiling patients 
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—— Observed concentrations 
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– – –  Population predicted concentrations 
Figure 7. Plots showing the best (left) and worst (right) fits of the start model 
after inclusion of covariates into the final model 
The difference in the plots of figure 6 and 7 are not apparent and not evident visually. 
Though the effect of covariate addition is evident in ∆ OFV presented in table 4 and the 
goodness of fit (GOF) plots (Figure 8). 
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Figure 8. Goodness of fit plot of observed vs. population predicted concentrations in 
start and final model 
The start model without covariates has a tendency to over-predict low CsA concentrations 
which reduces the fit significantly. Addition of covariates to the model greatly improves the 
fit. 
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Figure 9. Plot of weighted residuals vs. population predicted concentrations in start 
and final model 
Diagnostic plots of the weighted residuals shows that minimum / maximum WRES range 
drop from -3.2339 / 7.0121 in the start model to -3.8828 / 4.8198 in the final model with 
covariates. 
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3.3 THE FINAL MODEL FOR CYCLOSPORIN A 
The model that best described the data, based on the above mentioned criteria, was a 2-
compartment model with first order absorption, first order elimination and an absorption 
lagtime. A combined additive and proportional model was used to describe the distribution 
of random residual error, and an exponential error model described the inter-individual 
variability. The first-order conditional estimation method gave the lowest OFV.   
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Figure 10. Control file for the final model with all significant covariates 
Figure 10 shows the full control file with all the significant covariates. Also included are the 
starting estimates for THETA, OMEGA and SIGMA values, used to estimate fixed effects, 
inter-individual variability and residual variability, respectively. 
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Figure 11. Goodness of fit scatter plot of population predicted (PRED) and individual 
predicted (IPRE) vs. observed concentrations (OBS) of the final model 
GOF plots in figure 11 shows a good fit for the data. No significant deviation is seen in 
either population predicted or individual predicted plots. 
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Figure 12. Scatter plot of weighted residuals of the final model (ID# 1-20 = SUPER-CsA 
study, ID# 30-37 = MIMPARA study, ID# 51-65 & 67-72 = Age effect study) 
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3.4 VALIDATING THE MODEL 
3.4.1 Internal validation 
The parameter estimates obtained from the data-splitting are presented in figure 13. The 
majority of the estimated values are within ± 1 standard deviation. However, CL/F and 
ALAG does have one value each that is outside of ± 2 standard deviation. 
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Figure 13. Parameter estimates for the full data set (●) and the ten subsets containing 
~90 % of the population data (●) with ± 1 SD (– –) and ± 2 SD (- - -) 
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3.4.1.1 Examining the predictive performance of the population model 
Table 9. The prediction errors for predicted concentrations using all / none / only the 
first / the first and second available observed concentrations 
  
ALL NONE 1st 1st & 2nd 
  
    
Mean -7.25 -42.71 -69.30 -66.66 
SD 28.27 127.88 139.99 135.95 
95 % CI min. -24.77 -121.97 -156.07 -150.93 
ME (ng/ml) 
95 % CI max. 10.27 36.55 17.47 17.60 
 
 
    
Mean 64510.18 183866.57 188016.22 180250.51 
SD 17211.28 44022.25 61443.44 48174.34 
95 % CI min. 53842.52 156581.29 149933.18 150391.74 
MSE (ng/ml)2 
95 % CI max. 75177.84 211151.84 226099.26 210109.28 
 
 
    
Mean 164.49 283.80 287.28 281.61 
SD 20.80 34.42 49.52 38.99 
95 % CI min. 151.60 262.47 256.59 257.44 
RMSE 
(ng/ml) 
95 % CI max. 177.38 305.14 317.97 305.77 
 
 
     
Mean 0.01 0.09 0.15 0.14 
SD 0.05 0.24 0.25 0.23 
95 % CI min. -0.02 -0.05 -0.01 0.00 
AVERAGE 
SPEALL 
95 % CI max. 0.04 0.24 0.30 0.28 
 
 
    
SD SPEALL Mean 0.41 0.63 0.65 0.63 
Abbreviations; ME = mean prediction error, MSE = mean squared prediction error, RMSE = root 
mean squared error, SPE = standardized prediction error 
ME is used as a measure of bias and from table 9 it can be seen that the individual predicted 
concentrations have a slight tendency to be underestimated.  
The precision of the model is assessed by MSE and RMSE. Clearly the data set with all the 
available observed concentrations show the greatest precision. The data sets with none, only 
the first, or the first and second observation does not show any large degree of difference 
between them, but have significantly less predictive performance than the data set with all 
observations.  
Predictive performance was also tested with standardized prediction error. The estimated 
average values were all very close to zero, which is a good indicator for good fit. The 95 % 
CI should also include zero, which all the data sets did. Not surprisingly the full data set 
performed the best.  Standard deviation of SPE should be as close to 1 as possible to give the 
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best predictive performance. The model falls short in this test, and has lower values than 
desired [18]. 
Table 10. Objective function values of full input model with fixed parameter 
estimates from subgroups A-J 
Final model 12088.50 
Subgroups 
A 12116.57 
Mean Minimum 
B 12116.74 12108.65 12001.52 
C 12254.61 
D 12020.62 
E 12227.53 
Median Maximum 
F 12021.83 12098.04 12254.61 
G 12079.51 
H 12001.52 
I 12193.07 
Standard 
deviation 
Standard 
error of 
mean 
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J 12054.54 90.21 28.53 
 
A 95 % CI is obtained when OFV does not differ more than ≥ 3.84. In the developed model 
the OFV obtained from the final model varied greatly, when run with fixed parameter 
estimates from the 10 subgroups. Values ranged from 12001.52 to 12254.61, which indicate 
a lack of robustness. 
3.4.2 Confidence interval 
Table 11. Results from the Jackknife 
PK parameters Mean SD 95 % CI min. 95 % CI max. 
Clearance 25.54 1.30 25.18 25.91 
Central volume 78.69 3.25 77.78 79.60 
Intercompartmental clearance 20.53 1.95 19.99 21.08 
Peripheral volume 351.5 20.99 345.7 357.4 
Absorption rate constant 1.872 0.190 1.820 1.924 
Absorption lagtime 0.4495 0.0063 0.4477 0.4512 
 
Upon reviewing the individual Jackknife estimates (Appendix 7.7), it showed that the 
patients did not exhibit any significant influence on the parameters.  
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3.4.3 External validation 
Table 12. The prediction errors for predicted concentrations in the external 
group 
  
ALL NONE 1st conc. 1st week 
1st & 2nd  
weeks 
  
    
 
Mean 13.19 18.93 -2.10 8.20 -4.45 
SD 28.33 136.76 234.26 171.74 117.23 
95 % CI min. -4.37 -65.83 -147.30 -98.25 -77.11 
ME  
(ng/ml) 
95 % CI max. 30.75 103.70 143.09 114.64 68.21 
 
 
     
Mean 68162.36 94782.70 124617.96 100785.97 82416.73 
SD 42435.27 47882.74 70716.91 49887.68 48767.54 
95 % CI min. 41860.71 65104.67 80787.17 69865.27 52190.30 
MSE  
(ng/ml)2 
95 % CI max. 94464.01 124460.74 168448.76 131706.68 112643.16 
 
 
     
Mean 188.79 242.37 280.85 249.56 223.24 
SD 56.98 69.30 78.59 65.95 70.43 
95 % CI min. 153.47 199.42 232.14 208.68 179.59 
RMSE  
(ng/ml) 
95 % CI max. 224.11 285.32 329.55 290.44 266.89 
 
 
      
Mean -0.04 -0.04 0.01 -0.06 -0.06 
SD 0.08 0.48 0.76 0.48 0.44 
95 % CI min. -0.09 -0.34 -0.46 -0.36 -0.33 
AVERAGE  
SPEALL 
95 % CI max. 0.01 0.26 0.48 0.23 0.22 
 
 
     
SD SPEALL Mean 0.78 0.89 0.88 0.81 0.82 
Abbreviations; ME = mean prediction error, MSE = mean squared prediction error, RMSE = root 
mean squared error, SPE = standardized prediction error 
As expected, by including more concentration data points into the data set the prediction 
errors decrease. The amount of data points per week were between 3-4 observed 
concentrations. This was much more than the amount of data included for the internal 
validation, and thus the last column in table 9 and the two last columns in table 12 should not 
be compared directly. 
The 95 % CI for the standardized prediction error average included zero and the standard 
deviation was close to 1, indicating a good fit of the data. 
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4 DISCUSSION 
4.1 MODEL BUILDING  
Creating the input file necessary for NONMEM was a challenging task. 23 columns and 
5973 rows were filled with patient data. The input file was created and then double checked 
by another person to ensure validity of the file. 
A literature search in ISI Web of KnowledgeSM and PubMed gave no hits on PK population 
models using the same type of data set as the one used here. Previous studies have used one 
full 12-hours PK-profiling [26], three full12-hours PK-profiling performed at 3 weeks, 6 
months and 1 year post-transplantation [28], one full 24-hours PK-profiling [29], or limited 
or rich sampling strategy for AUC-estimation and PK-profiling [27, 41]. The data set used 
for this model differs from other previous studies by incorporating a large amount of CsA C0 
and C2 concentration data before and after PK-profiling for the SUPER-CsA patients [43].  
Creating the control file with the desired compartment model proved to be difficult. Guides 
provided by http://www.accp1.org/pharmacometrics/index.html [61] and control files 
provided by Live Storehagen [50] were used as a basis to build the necessary steps in the 
control files. More elaborate modifications of the control files were done using the user guide 
provided with the NONMEM application [7]. 
As mentioned earlier, many different PK population models have been developed for 
modelling of CsA. The varying type and amount of data used for the input file may result in 
different models which best describes the data set in question. A study performed by Wu et 
al. used a 1-compartment model to describe the CsA data. It was not mentioned if any other 
models were tested for their data set. This seemed unusual as most other studies use a more 
complex model than that. A highly lipophilic drug such as CsA would most likely need a 
peripheral compartment, therefore the model screening process was most focused on 2- and 
3-compartment models. Highly inconsistent reporting of model specifications meant that the 
screening process had to be widened to include many different absorption methods. 
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4.1.1 1. order input, 1-compartment with and without lagtime 
ADVAN2 and TRANS2 subroutine was used to code the control file for the 1-compartment 
models. The models did not show a good fit for the data. With both individual and 
population predicted concentrations being strongly underestimated around peak 
concentrations and overestimated beyond C2. Inclusion of lagtime did improve this to some 
extent. OFV for the 1-compartment model without lagtime was 13035.80 and dropped to 
12807.03 when lagtime was included. The significance of lagtime meant that it should be 
tested in all later models. The run times for these two models were very fast, with an average 
of less than five minutes [19]. 
4.1.2 1. order input, 2-compartment without lagtime 
The subroutine for 2-compartment model was coded with ADVAN4 and TRANS4. A 
slightly lower OFV of 12805.39 was not statistically significant, but the better fit of the 
elimination profile justified further testing of this model [19]. 
4.1.3 1. order input, 2-compartment with lagtime 
Subroutine coding for this model was similar to the regular 2-compartment with just the 
lagtime function added. This model showed a good fit for the data, but peak concentrations 
was not reached by predicted concentrations and needed addressing. The model used the 
FOCE estimation method and eventually reached lowest OFV at 12403.00. When tested with 
the FO estimation method the resulting performance was significantly less, with a rise in 
OFV to 12553.47. Later models were therefore only coded with FOCE. The model did have 
a problem with instability between runs in the beginning. By making the interval for the 
starting estimates of the parameters smaller, the model did performed better without hitting 
the limits. 
 61 
4.1.4 0. order input, 2-compartment with lagtime 
ADVAN3 was used to code the subroutine of the 2-compartment model with zero order 
input. The model showed highly variable estimates of the parameter and a high OFV of 
12954.06. The serious lack of robustness of this model meant that it was discarded in favor 
of other models. The run time for the 2-compartment models up until this point were good 
and most runs finished between 10-20 minutes [19]. 
4.1.5 1. order input, 3-compartment with and without lagtime 
The 3-compartment models were coded with subroutine ADVAN12. The model without 
lagtime did not perform well with an OFV of 12776.7 and a runtime averaging at 50 minutes. 
Peak concentrations were not well predicted. Inclusion of lagtime showed improvement 
much like in the other models. OFV dropped to 12457.45, but run time increased with 
approximately 20 minutes. Though initial model testing showed that the 3-compartment 
model gave a low OFV value, it was not chosen for further investigation mainly due to its 
instability. Small changes in the start values for parameter estimates would throw the model 
off course, and yield noticeable change in model performance and parameter estimation [19]. 
4.1.6 2-compartment with Erlang distribution 
To incorporate the Erlang distribution into the 2-compartment control file, a more complex 
subroutine was used. ADVAN5 SS5 was used to make the user defined Erlang absorption 
profile. Describing the data using the Erlang distribution did produce a good fit for the 
delayed and flat absorption profile of CsA, but severely overcomplicated the model. Run 
time increased from an average of 30 minutes for a regular 2-compartment model with 
lagtime to between 4-24 hours for the acceptable models with Erlang distribution. Compared 
to the final model, the Erlang model had a higher OFV value. The number of Erlang 
compartments was tested according to the criteria mentioned in paragraph 2.2. The resulting 
OFVs showed that improvement could be seen from 1 to 4 Erlang distribution 
compartments. Adding the fifth Erlang compartment, while retaining the same start values 
for the parameter estimates, gave a significant rise in OFV. When adding the sixth Erlang 
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compartment a drop in OFV was seen. The downside was that runtime from this point on 
exceeded 72 hours. To be useful in the clinical add-on study, runtime would have to be 
approximately 24 hours, as the model would be set to run over night, and results would be 
needed for the next morning. Adding more compartments after this point did not show any 
improvement in fit, and gave an increase of OFV [19, 27, 50].  
Storehagen [50] used the PK-profiling of the SUPER-CsA study [43] and the MIMPARA 
study [45] and found the Erlang distribution with 6 Erlang compartments to describe the data 
the best. With only these data the model also performed much faster, with the run time (29 
minutes and 15 seconds) well below the criteria set for the model developed in this thesis. 
The difference is most likely due to the amount of data used by Storehagen [50], 210 
observed concentrations, compared to the amount of data used for the model in this thesis, 
1027 observed concentrations. The PK-profiling is done no closer than one month post-
transplantation, so that the patients have had time to stabilize their physiology. The data set 
used in this thesis was from 0 weeks and up to 17 weeks post-transplantation. There are large 
time dependent variations that are possibly overlooked when using only PK-profiling. The 
large amount of data used in this thesis may possibly require simpler models to match the 
criteria set, while less data can employ more elaborate models without defying the same 
criteria. 
4.2 ANALYZING FOR COVARIATES 
Reviewing the graphical representation of post hoc etas vs. covariates (Appendix 7.3) shows 
that many covariates influences the PK parameters of the model. However, when screening 
for covariates estimation show that most of the covariates are in fact not statistical 
significant. Many covariates did show significance during forward inclusion, but most 
eventually did not prove to be significant when run through backwards deletion.  
As mentioned earlier, Storehagen [50] used some of the data from the same studies as used 
in this thesis. The covariate screening for that study included weight (kg), creatinine 
clearance (ml/min), age (years), height (cm), gender, post-transplantation period (weeks) and 
steroid dose at the pharmacokinetic day (mg). The graphical analysis then showed that 
weight, age and creatinine clearance tended to correlate with some of the PK parameters, and 
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therefore needed further investigation. Though ultimately, the only significant covariate was 
age on CL/F [50]. The large amount of significant covariates for the developed model in this 
thesis is therefore surprising as also many other studies have only a few or no significant 
covariates, but this may be due to the large amount of data over a relatively long time period 
available in the present study [18, 26-29, 42].  
All linear models gave significant results on some combinations of covariate and parameter. 
Screening with the proportional models did not give any significant results. 
In the preliminary models it was evident that approximately the first 16 days after 
transplantation showed signs of highly variable concentration predictions. This could only be 
seen in the patients from the SUPER-CsA study, which provided more data than just PK-
profiling. It was decided to test more rigorously for any relationship between predicted 
concentrations and covariates influencing this time period. The goodness of fit plots in figure 
8 of the start model shows difficulty in modelling this first time period after transplantation. 
Concentrations are highly over predicted as can be seen in the quality of fit plots 
(Observed/Predicted over time) of the start model (Appendix 7.4). Many low plasma 
concentrations during this time are predicted wrongly by a factor of approximately two. The 
early periods after transplantation are plagued with the body going through a lot of stress. 
The operation procedure for renal transplantation includes going through the stomach which 
will most definitely impact the absorption and bioavailability of CsA. Altered 
gastrointestinal motility is to be expected. A factor that might also influence this time period 
is the switch from i.v. Solu-Medrol® during transplantation to oral prednisolone after 
transplantation. These influences are reflected by the high variability in observed 
concentration. Though it should not be ruled out that assay may also play a role. By 
incorporating time dependent covariates such as post-transplantation time and steroid dose, 
much of this variability is accounted for. [62] GOF plots of the final model (Figure 8 and 
Figure 11) clearly show an improvement in fit with a more even distribution. Steroid dose 
(mg), in the form of prednisolone, proved to be significant on CL/F, ka, V1/F and V2/F, 
while post-transplantation time (weeks) was significant when applied to ALAG, ka, V1/F 
and V2/F. Some of this was expected as Saint-Marcoux et al. [26], Wu et al. [18] and 
Rosenbaum et al. [35] have already incorporated post-transplantation time in PK population 
models for CsA. 
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Covariates such as BMI, gender, height, post-transplantation time and steroid dose gave 
many significant changes in OFV of the start model. They were tested with many different 
equations, and gave overlapping answers. Only a few were selected for backwards deletion. 
The choices were based on which covariate that gave the largest drop in OFV, and the 
clinical significance of the covariate was also weighted. 
The effect of weight, BMI and LBM on volume parameters were significant, not surprisingly. 
Patients commonly gain weight up to 10 % after transplantation. This increase can be 
attributed to decreased physical activity coupled with inappropriate food intake, also possibly 
due to administration of high doses of steroids, and the move from a catabolic end stage 
renal disease (ESRD) phase to a more anabolic post-transplantation phase. [18] 
Gender did produce significant changes in OFV when added to the model. Significance was 
shown for CL/F, ka, VC/F and VP/F. This was surprising as most other studies did not find 
this covariate to improve models. [18, 34] When reviewing the demographics for the two 
genders, it shows that there is not much difference in mean values for age, height or BMI. 
Females do however have a significantly lower weight of ~15 kg and this correlates with the 
LBM being ~10 kg lower. This weight difference could be the source of gender as a 
significant covariate. 
Storehagen [50] and Wu et al. [18] have previously shown age as a significant covariate for 
CL/F. Physiological changes related to increasing age include loss of liver mass and reduced 
blood flow to the liver, which influences the metabolism and clearance of CsA [44, 50]. Age 
was therefore expected to be a significant covariate, but this could not be seen in this 
population. Preliminary screening indicated some significance, but age as a continuous 
covariate did not prove to be significant after backwards deletion.  
As mentioned earlier, CYP 3A5 genotype did give a significant change in OFV 
during forward inclusion. Even though it should be tested further for possible 
inclusion in the final model with all the significant covariate, it was left out because 
of the analysis required for genotype identification is not clinically available yet. 
This rendered it not efficient enough to be used in the clinical setting of the proposed 
add-on study for external validation. This being said, it may prove to be useful for 
later studies. It was also mentioned that CYP enzymes work in concert with P-gp 
 65 
transporters. Though the effect of P-gp mutations might have influenced the CsA 
data, it was not tested for this model. 
Diabetes did not prove to be a significant covariate, but this may be due to the fact that it was 
not detailed specifically. The coding for diabetes included only non-diabetic = “FLAG=1” or 
type 1 diabetes = “FLAG=2”. As some patients also had type 2 diabetes before undergoing 
renal transplantation and some patients developed type 2 diabetes after the transplantation, a 
more specific coding for diabetes might have proven useful for the model. This was however 
not tested for this model. 
Overall the peak concentrations for the PK-profiling patients were estimated more accurately 
after inclusion of covariates into the model. Individual predications were not markedly 
affected, while population predictions show signs of improvement. The most notable effect 
of covariate inclusion is the greatly improved fit in the first time period after transplantation. 
Although many sources of variability was identified and quantified, there is still some 
variability that is unaccounted for in this present model. Differentiation of oral prednisolone 
and i.v. Solu-Medrol®, a more specific diabetes covariate coding, a covariate coding for post-
transplantation time after 3 months, and screening for influence of CYP enzymes and P-gp 
transporters may be needed to improve upon the developed model. 
4.3 THE FINAL MODEL FOR CYCLOSPORIN A 
After a preliminary screening of different models, the 2-compartment model with lagtime 
showed the most promise. Though stability problems had to be overcome, the model gave a 
good fit and had an acceptable run time. Run time was one important criterion, as this model 
would be implemented in a clinical study. Validation of the model would also be less 
cumbersome, and less computational power would be needed to run the model in 
NONMEM. Possibly by increasing computational power other models might have proven to 
be useful as well, but this was not tested. The selected model was tested rigorously, before 
inclusion of covariates.  
For the final model there is an even distribution in the scatter plots of weighted residuals, 
which is acceptable. 
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The goodness of fit scatter plots of the final model shown in figure 11 shows a good 
correlation between observed and predicted concentrations, which indicates that the model 
fits the observed concentrations. However, it can be seen that the model does have problems 
in predicting lower concentrations. A slight over-prediction for low level concentration is 
observable, but is considerably improved in comparison to earlier models during screening. 
This is also evident when reviewing the individual fits (Appendix 7.6). Under-prediction for 
higher concentrations can be seen for some patients, in particular around peak 
concentrations. Prediction problems were somewhat addressed by the inclusion of covariates, 
but none the less more elaborate models and larger data sets may be needed to improve the 
model.  
One problem that was not resolved was the high degree of under-prediction for 
concentrations observed beyond 2000 hours (~12 weeks). As can be seen on the quality of fit 
plots (Appendix 7.5), there are four patients that have observations after 2000 hours. Patient 
no. 8 provides observations up to ~2200 hours, patient no. 6 and 9 provide observations up to 
~2500 hours, and patient no. 10 provides observations up to 3000 hours. There are too few 
observations for the model to correctly predict concentrations at this point, when compared 
to observations before 2000 hours. Individual predictions are more accurate than population 
predicted concentrations, which is to be expected. As mentioned in paragraph 2.1.1 Saint-
Marcoux et al. [26] coded the post-transplantation time in three intervals of < 2 weeks, 
between 2 weeks and three months, and > 3 months. A more appropriate covariate coding 
could have corrected this under-prediction, but this theory was not tested. 
Another point that should be mentioned is that the model incorporates data from directly 
after the transplantation, while in the clinical setting of the proposed add-on study patients 
will not be available for the study until approximately one week post-transplantation. During 
the first days after transplantation patients are in intensive care. Highly variable CsA 
concentrations were observed during this first week in the SUPER-CsA [43] data available 
for model development. The high degree of variability may possibly influence the model in 
negative way that may be seen once the model is applied in a clinical setting. Some possible 
reasons for this variability have been discussed in paragraph 4.2. The limitations caused by 
the first week post-transplantation were not fully explored in this thesis. 
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4.4 VALIDATING THE MODEL 
Validation can be viewed as an objective evaluation of the predictability of a model, and 
assess whether deficiencies of the model will have a noticeable effect. The validation process 
will also evaluate the clinical applicability of the model. In literature the different methods 
for validation is discussed, but one cannot conclude which method that is best. It is still an 
evolving science, and it is the personal preference of the analyst that usually decides the 
choice. Justification for any choice should be given [5, 6, 63]. 
The technique used to examine the predictive performance of the model was recommended 
by the Food and Drug Administration. The data-splitting gave very variable OFV and clearly 
showed that the model has a lack of robustness. The difference between the maximum and 
minimum value were 253.09, which is significantly more than the maximum allowed value 
of < 3.84. Parameter values however were very consistent for the developed model. No 
significant deviation can be seen in the estimated parameter values for the 10 subsets. 
The data set used to develop this model was different from most other data set used 
previously, by including a large amount of data before and after the 12-hours PK-profiling. 
This meant that while performing predictive performance check, the observed concentrations 
chosen to be included in the subset for the remaining ~10 % could not be chosen as other 
studies have done. Usually the observed concentrations included are C0, C1, C2 and/or C3, 
and the predictive performance is evaluated from AUC0-4 or AUC0-12 calculations [50, 64]. 
This could not be done for the data set used in this model because there were 11 patients 
(SUPER-CsA patient no. 1-6, 13, 15-17 and 20 [43]) that did not have PK-profiling 
performed at all, only routine follow-up concentrations. Therefore the observed 
concentrations included were just the first and/or the second concentration for that specific 
patient. Predictive performance was then compared by calculations of the individual 
predicted concentrations. AUC0-12 was not used in this case. Results showed that precision 
were higher when “no observed concentrations” and “the first and second observed 
concentrations” were used, than when only the “first observed concentration” was included 
in the input file. This may seem unusual, but upon reviewing the observed concentrations 
that are included, it is evident that the first concentration is a highly variable concentration 
measured quite recent after the transplantation. This is especially the case for the SUPER-
CsA [43] patients that provided much more data. As mentioned earlier, this time period is 
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plagued by many factors that might cause a high degree of inter-individual and residual 
variability. The patients undergo many physiological changes that may affect the overall CsA 
concentrations and effects. Another point that might have affected the precision in this 
validation test is the fact that C0 and C2 measurements were not differentiated. The first 
observed concentrations that were included in the input file for validation was always a C0 
measurement for the MIMPARA [45] patients and the patients from the age effect study 
[44]. The SUPER-CsA [43] patient provided first observed concentrations that could be C0 
or C2. A small absolute estimation error for a C0 measurement will affect the overall 
precision for the entire group in a larger degree than the same absolute estimation error for a 
C2 measurement, but this is clinical reality. Inclusion of two concentration data points will 
improve the precision of the model on the basis that the model has more data to build upon. 
The Jackknife technique for acquiring 95 % CI was preferred over bootstrapping because it 
required less computation. The 49 Jackknife runs required approximately 48 hours to 
complete. The result was acceptable, though the lack of robustness of the model may have 
affected this estimation. This is evident as patient no. 2, 16, 20, 33, 34, 65 and 69 gave very 
high estimates of VP//F, which were close to the upper level range for starting estimates of 
this parameter (Appendix 7.7). This was a problem with the model from the beginning. Lack 
of robustness meant that the model parameter estimates could easily shoot up to high levels 
that seemed unrealistic. The final models variable parameter estimates which gave a mean 
value for VP//F of 351.5 L and maximum value of 399 L is acceptable, but seem high when 
compared to other studies such as Rousseau et al. [27], and Saint-Marcoux et al. [26] which 
had 133 L and 129.4 L, respectively.  
External validation of the model did show the same tendencies as for the internal validation. 
Inclusion of the first observed concentration showed a large deviation when compared to 
inclusion of none or more observed concentrations. This anomaly has been pointed out 
earlier when discussing the internal validation. Overall the results were as expected, with 
improvements in bias and precision, when more observed concentrations are included in the 
data set.  
The biggest problem of the developed model was discovered during validation. The lack of 
robustness caused deterioration of all the estimated values. This was a problem that occurred 
after inclusion of the significant covariates. Though the covariates proved to be statistically 
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significant, it is possible that the clinical significance of their effect is overestimated. The 
criteria set up for inclusion of covariates in to the final model, will need revision to possibly 
only keep covariates of the greatest strength for the final model. As the new criteria will be 
stricter this approach will not interfere with statistical significance as defined by the 
maximum likelihood approach used by NONMEM.  
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5 CONCLUSIONS 
By using the non-linear mixed-effect modelling program NONMEM a pharmacokinetic 
population model was developed for renal transplant patients receiving cyclosporine A. This 
model may in future settings be used to design dosage regimens for other patients. 
Optimization of therapeutic drug monitoring in renal transplant patients receiving 
cyclosporine A was the overall goal of the work of this thesis. 
Development of the pharmacokinetic population model was done in a stepwise manner. A 
screening process where different compartment models were tested with different absorption 
profiles eliminated all but one model, which was chosen for further development. The 2-
compartment model with an absorption lagtime gave the best fit with acceptable run time for 
the cyclosporin A data. 
The 2-compartment model with an absorption lagtime was improved upon by adding patient 
specific covariates. These covariates were added to explain the inter-individual variations 
seen in the pharmacokinetic parameters. The large amount of data used produced many 
significant covariates, but only the most significant were chosen for inclusion in the model. 
The covariates that gave the most significant impact on the model were the time-dependent 
covariates steroid dose (mg) and post-transplantation time (weeks). By adding these 
covariates the error in predicted concentrations in the first 2 weeks after transplantation was 
significantly less. However many covariates gave very variable estimates, which may 
indicate that they have an overestimated clinical effect, and could possibly be removed from 
the model. A stricter screening procedure for covariates may need to be implemented. 
Results from the internal validation performed showed that the model had a lack of 
robustness. This may possibly be caused by the large amount of covariates added to the 
model. The model is not able to deal effectively with changes in start estimates for the 
pharmacokinetic parameters. However results do show that the model describes the 
cyclosporin A data in a good manner. More external testing may be needed to prove the 
appropriateness and the effectiveness of the model, as external validation is the strongest 
evidence for a good fit. 
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Further refinement may be needed to improve upon the stability of the model, but this model 
does provide a good basis upon which a dosage regimen for cyclosporin A may be designed 
and tested clinically. 
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7 APPENDIX 
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7.1 PARTIAL INPUT FILE FOR NONMEM 
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7.2 CONTROL FILES FOR NONMEM 
7.2.1 1-compartment model with lagtime 
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7.2.2 2-compartment model with lagtime 
 
 85 
7.2.3 2-compartment model with zero order absorption 
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7.2.4 2-compartment model with 4 Erlang compartments 
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7.2.5 3-compartment model with lagtime 
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7.3 PLOTS OF POST HOC ETAS VS. COVARIATES OF START 
MODEL 
 89 
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7.4  QUALITY OF FIT PLOT OF THE START MODEL 
 
7.5 QUALITY OF FIT PLOT OF THE FINAL MODEL 
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7.6 INDIVIDUAL FITS 
Circles: Observed concentrations; Red: Individual post hoc predicted concentrations;  
Blue: Population predicted concentrations 
 93 
 94 
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7.7 JACKKNIFE RESULTS 
Patient excluded PK 
parameters 
Final  
model 1 2 3 4 5 6 7 8 
CL/F 26.1 25.6 23 26.1 26.1 26.1 25.9 25.4 23.2 
VC/F 77.7 78.8 78.2 78 77.9 77.8 77.9 77.9 78.2 
Q/F 20.5 21.3 20.3 20.4 20.4 20.4 20.5 19.4 20.3 
Vp/F 342 352 399 342 342 344 342 343 358 
ka 1.88 1.9 1.83 1.86 1.86 1.9 1.79 1.74 1.7 
ALAG 0.452 0.454 0.438 0.449 0.446 0.441 0.455 0.438 0.449 
          
Patient excluded PK 
parameters 9 10 11 12 13 14 15 16 17 
CL/F 25.6 26.2 26.1 25.8 26.1 24.5 26.6 23.8 26.1 
VC/F 77.8 77.9 77.9 77.7 77.9 77.6 76.9 87.8 78.1 
Q/F 21.1 20.4 20.4 21 20.6 17.7 20.3 17 20.4 
Vp/F 344 342 342 350 342 322 343 399 342 
ka 2.07 1.86 1.85 1.75 1.79 2.06 2.07 1.99 1.81 
ALAG 0.454 0.451 0.448 0.448 0.459 0.447 0.434 0.451 0.445 
          
Patient excluded PK 
parameters 18 19 20 30 31 32 33 34 35 
CL/F 26.1 28.2 25.6 24.1 23 26.1 24.9 26.3 26.2 
VC/F 77.9 77.5 79.8 78 77.3 77.9 77 78.6 77.8 
Q/F 20.4 22.9 19.7 28.2 21.3 20.4 20.5 18.5 20.5 
Vp/F 342 345 398 371 350 338 397 399 342 
ka 1.81 1.87 1.44 1.62 1.84 1.86 1.82 1.64 1.93 
ALAG 0.448 0.465 0.459 0.447 0.45 0.449 0.448 0.452 0.445 
 
 
 
 
 
 
 
         
          
 99 
          
Patient excluded PK 
parameters 36 37 51 52 53 54 55 56 57 
CL/F 26 26.1 25.9 26.7 23.1 27 25.8 23 25.1 
VC/F 78.2 77.9 77.7 77.8 77.9 77.8 78 78.9 78.3 
Q/F 20.4 20.4 20.5 20.5 18.9 21.3 20.4 17.5 21.8 
Vp/F 342 342 326 356 344 320 339 341 346 
ka 1.84 1.86 1.67 1.71 1.86 1.92 1.82 1.82 1.85 
ALAG 0.443 0.447 0.449 0.443 0.452 0.443 0.455 0.455 0.446 
          
Patient excluded PK 
parameters 58 59 60 61 62 63 64 65 67 
CL/F 26.6 26.1 26.1 26.1 26 25.6 27.4 24.1 26.2 
VC/F 78.5 77.9 77.9 77.9 77.9 77.8 78.1 89.6 77.9 
Q/F 17.5 20.6 20.4 20.6 20.4 19.6 19.6 20.5 20.7 
Vp/F 342 342 342 345 343 353 344 399 342 
ka 2.23 1.85 1.86 1.85 1.85 1.86 1.94 1.84 1.82 
ALAG 0.464 0.449 0.446 0.453 0.447 0.449 0.446 0.447 0.461 
          
Patient excluded  
   
PK 
parameters 68 69 70 71 72 
    
CL/F 26.1 23 26.1 27.8 23 
    
VC/F 77.9 94.8 77.9 75.1 77.9 
    
Q/F 20.4 20.4 20.4 28.5 20.4 
    
Vp/F 342 399 342 360 344 
    
ka 1.86 1.99 1.86 2.12 2.79 
    
ALAG 0.45 0.461 0.451 0.447 0.45 
    
 
